The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 2050-2060

  Schneider Merck, T ^a   Borbath, I ^a,b   Charette, N ^a   De Saeger, C ^a   Abarca, J ^a   Leclercq, I ^a   Horsmans, Y ^a,b   Starkel P ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Apoptosis; DEN; FAS; FTS; Hepatocellular carcinoma; Ras oncogene

Indexed keywords

CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; DIETHYLNITROSAMINE; FARNESYLTHIOSALICYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ENZYME ACTIVATION; ENZYME ASSAY; GENE ACTIVATION; GENE ACTIVITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MALE; NICK END LABELING; NONHUMAN; ONCOGENE; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE HISTOCHEMISTRY; RAT; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; DIETHYLNITROSAMINE; FARNESOL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MODELS, ANIMAL; RATS; RATS, WISTAR; SALICYLIC ACIDS;

EID: 67649378624     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.014     Document Type: Article

References (36)

1. Llovet M.J., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (2008) S20-S37
2. Thorgeirsson S.S., Lee J.S., and Grisham J.W. Molecular prognostication of liver cancer: end of the beginning. J Hepatol 44 (2006) 798-805
3. Bos J.L. The ras gene family and human carcinogenesis. Mutat Res 195 (1988) 255-271
4. Adjei A.A. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 93 (2001) 1062-1074
5. Haklai R., Gana Weisz M., Elad G., et al. Dislodgment and accelerated degradation of ras. Biochemistry 37 (1998) 1306-1314
6. Elad G., Paz A., Haklai R., Marciano D., Cox A., and Kloog Y. Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452 (1999) 228-242
7. Marom M., Haklai R., Ben-Baruch G., Marciano D., Egozi Y., and Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270 (1995) 22263-22270
8. Zundelevich A., Elad-Sfadia G., Haklai R., and Kloog Y. Supression of lung cancer tumor growth in a nude Mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 6 (2007) 1765-1773
9. Jansen B., Schlagbauer-Wadl H., Kahr H., et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci 96 (1999) 14019-14024
10. Weisz B., Giehl K., Gana-Weisz M., et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18 (1999) 2579-2588
11. Santen R.J., Lynch A.R., Neal L.R., McPherson R.A., and Yue W. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Anticancer Drugs 17 (2006) 33-40
12. Egozi Y., Weisz B., Gana-Weisz M., Ben-Baruch G., and Kloog Y. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. Int J Cancer 80 (1999) 911-918
13. Reif S., Weis B., Aeed H., et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J Hepatol 31 (1999) 1053-1061
14. Ogato N., Kamimura T., and Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 13 (1991) 31-37
15. Gu J.R., Hu L.F., Cheng Y.C., and Wan D.F. Oncogenes in human primary hepatic cancer. J Cell Physiol 4 (1986) 13-20
16. Richards C.A., Short S.A., Thorgeirrson S.S., and Huber B.E. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis. Cancer 50 (1990) 1521-1527
17. Yoshida T., Hisamoto T., Akiba J., et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25 (2006) 6056-6066
18. Calvisi D.F., Ladu S., Gorden A., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
19. Da Silva Morais A., Saliez A., Leclercq I., Horsmans Y., and Stärkel P. Inhibition of the ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci 114 (2008) 73-83
20. Newell P., Villanueva A., Friedman S.L., Koike K., and Llovet J.M. Experimental models of hepatocellular carcinoma. J Hepatol 48 (2008) 858-879
21. Lee J.S., Chu I.S., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36 (2004) 1306-1311
22. Schiffer E., Housset C., Cacheux W., et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41 (2005) 307-314
23. Marciano D., Ben-Baruch G., Marom M., Egozi Y., Haklai R., and Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38 (1995) 1267-1272
24. Borbath I., Leclercq I., Moulin P., Sempoux C., and Horsmans Y. The PPARgamma agonist pioglitazonz inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 43 (2007) 1755-1763
25. Bannasch P., Haertel T., and Su Q. Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol 31 (2003) 134-139
26. Dragan Y.P., Campbell H.A., Baker K., Vaughan J., Mass M., and Pitot H.C. Focal and non-focal hepatic expression of placental glutathione S transferase in carcinogen-treated rats. Carcinogenesis 15 (1994) 2587-2591
27. Ying T.S., Sarma D.S.R., and Faber E. The sequential analysis of liver cell necrosis. Inhibition of diethylnitrosamine- and dimethylnitrosamine induced acute liver cell death by posttreatment with diethyldithiocarbamate. Am J Pathol 99 (1980) 159-174
28. Teufel A., Staib F., Kanzler S., Weinmann A., Schulze-Bergkamen H., and Galle P.R. Genetics of hepatocellular carcinoma. World J Gastroenterol 13 (2007) 2271-2282
29. Haklai R., Elad-Sfadia G., Egozi Y., and Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61 (2008) 89-96
30. Kanzler S., and Galle P.R. Apoptosis and the liver. Semin Cancer Biol 10 (2000) 173-184
31. Houston A., and O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4 (2004) 321-326
32. Zhang B., Prendergast G.C., and Fenton R.G. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 62 (2002) 450-458
33. Nordstrand M., and Stenius U. Fas-mediated apoptosis is attenuated in preneoplastic GST-P-positive hepatocytes isolated from diethylnitrosamine-treated rats. Cell Biol Toxicol 15 (1999) 239-247
34. Czaja M.J. The future of GI and liver research: editorial perspectives III. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastrointest Liver Physiol 284 (2003) G875-G879
35. Suhara T., Kim H., Kirshenbaum L.A., and Walsh K. Supression of AKT signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in AKT-mediated Fas ligand regulation. Mol Cell Biol 22 (2002) 680-691
36. Sharma K., Wang R.X., Zhang L.Y., et al. Death the Fas way: regulation and pathophysiology of CD 95 and its ligand. Pharmacol Ther 88 (2000) 333-347